Web14 hours ago · In one set of experiments, H1975 cells were treated with cisplatin (12.5 or 25 μM (Cisplatin Ebewe, Apoteket Sverige AB, Stockholm, AB, SE)) for 48 h. The EVs were isolated from about 50 to 75 ml cell culture media/sample which was collected and cleared from cell debris by centrifugation, first for 5 min at 200 RCF and thereafter for 20 min at ... WebFDA granted accelerated approval in December 2024 to enfortumab vedotin-ejfv for patients with locally advanced or metastatic urothelial cancer who have received a PD-1 or PD-L1 inhibitor and a...
Differential damage and repair of DNA-adducts …
WebJun 29, 2024 · Data from neoplastic cells indicate that cisplatin-induced genotoxic lesions (formation of platinum DNA adducts) and increased levels of oxidative stress are the main mechanisms in inhibiting cell division. 8 On the other hand, initial observations of the peripheral nervous system showed a correlation between the severity of neuropathy and … WebCisplatin adducts are Guanine-Guanine (GG) DNA intrastrand cross links caused by the chemical compound Cisplatin. Cisplatin is used as a chemotherapy agent that contains … raymond perreault
In vivo Glioblastoma Therapy Using Targeted Liposomal Cisplatin
WebPositive control (s): RNA/DNA. Alternate Names for Cisplatin Modified DNA Antibody (CP9/19) - BSA Free ICR4 Limitations This product is for research use only and is not … WebJun 3, 2013 · Purpose Epidermal growth factor receptor is overexpressed in metastatic triple-negative breast cancers (mTNBCs), an aggressive subtype of breast cancer. Our randomized phase II study investigated cisplatin with or without cetuximab in this setting. Patients and Methods Patients who had received no more than one previous … WebApr 1, 2024 · Preclinical studies have revealed that anti-EGFR monoclonal antibody (mAb) cooperates synergistically with cisplatin or 5-fluorouracil to exert a growth-inhibitory effect on NPC cells [11]. These experimental findings are consistent with the clinical observations from a prospective phase II clinical trial of combination anti-EGFR mAb with ... simplify 1 1/3